The majority owner of the Barryroe oil field off the coast of Cork staved off bankruptcy with an examinership bid last July. Now Larry Goodman plans to green the company in an investment plan before the High Court.
The value of Ireland's oldest book seller has risen by €3m to €70m. Shareholders are now being rewarded again as the books and stationary retailer looks to a bright future.
The medtech firm began to shed money until there was literally "no more gas in the tank". The appointment of an interim examiner by the High Court today has triggered eleventh-hour working capital funding that will pay staff and keep the business afloat.
The Irish medtech, which has suffered multi-million losses since its IPO in 2021, is seeking court protection from its creditors. Unusually for such a petition, it is so cash poor it can't even fund itself through the 100-day examinership process.
When Covid-19 decimated revenue from energy projects, Norman Crowley refocused his business on its data-crunching software. Now CoolPlanet is adding mining EVs to its offering and Crowley is upfront about what works and what doesn’t (especially livestock farming).
Gavin McConnon and Brendan Spratt, who co-own Dumbbell Fitness Ltd, have run out of road for their chain of F45 gyms. In a letter to their creditors, they give their account of what went so wrong for the company.
Louise Kennedy has dressed politicians, movie stars, and royalty. But what drives the designer to succeed, and, as she celebrates 40 years in the industry, what are her plans for the future?
Having failed to raise €50m, Bio-Marine Ingredients Ireland Ltd is using the recently introduced Scarp process to restructure its debts. But first, it wants the High Court to grant it protection from its many creditors.
Now able to offer employee health and pension cover in 30 countries through a seamless online system, the start-up founded as Yonder believes it can grow this market with new funding led by Sweden’s EQT Ventures.
Given the size of the business, the overall profit margins at McCabes Pharmacy are relatively modest. However, based on an analysis of its performance over a five year period, it has cleverly positioned itself for a transaction.
© 2025 Currency Media Limited
